Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPTH Bio-Path	$4.12 -1.9%	$5.50	$2.70 ▼ $44.80	$2.80M	0.35	1.16 million shs	1.93 million shs
DMAC DiaMedica Therapeutics	$2.46 -1.2%	$2.85	$1.50 ▼ $4.75	$93.38M	1.69	42,467 shs	17,234 shs
INNT Innovate Biopharmaceuticals		$0.97	$0.37 ▼ $1.67	$8K	-0.39	525,982 shs	N/A
VTL Vital Therapies	$1.27 +5.0%	$8.88	$0.15 ▼ $9.75	$53.81M	3.51	21.62 million shs	280,404 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPTH Bio-Path	+30.03%	+33.33%	-7.89%	-49.15%	-85.47%
DMAC DiaMedica Therapeutics	-4.23%	-1.97%	-11.70%	-11.70%	+44.77%
INNT Innovate Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	-99.92%
VTL Vital Therapies	0.00%	-13.57%	-8.33%	+1.68%	-26.22%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPTH Bio-Path	1.4666 of 5 stars	3.5	2.0	0.0	0.0	2.8	0.0	0.6
DMAC DiaMedica Therapeutics	0.8106 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.0	0.0
INNT Innovate Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VTL Vital Therapies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPTH Bio-Path	3.00	Buy	$40.00	870.87% Upside
DMAC DiaMedica Therapeutics	3.00	Buy	$7.00	184.55% Upside
INNT Innovate Biopharmaceuticals	N/A	N/A	N/A	N/A
VTL Vital Therapies	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest VTL, BPTH, DMAC, and INNT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/18/2024	BPTH Bio-Path	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
3/27/2024	BPTH Bio-Path	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $40.00
3/21/2024	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
3/21/2024	DMAC DiaMedica Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$7.00 ➝ $6.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPTH Bio-Path	N/A	N/A	N/A	N/A	$0.71 per share	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A
INNT Innovate Biopharmaceuticals	N/A	N/A	N/A	N/A	($0.27) per share	N/A
VTL Vital Therapies	N/A	N/A	N/A	N/A	$0.29 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPTH Bio-Path	-$16.08M	-$40.80	N/A	N/A	N/A	N/A	-375.74%	-248.63%	5/10/2024 (Estimated)
DMAC DiaMedica Therapeutics	-$19.38M	-$0.62	N/A	∞	N/A	N/A	-40.07%	-37.90%	5/20/2024 (Estimated)
INNT Innovate Biopharmaceuticals	-$27.05M	N/A	N/A	N/A	N/A	N/A	N/A	-234.42%	N/A
VTL Vital Therapies	-$41.47M	N/A	0.00	∞	N/A	N/A	-235.33%	-182.35%	N/A

Latest VTL, BPTH, DMAC, and INNT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/20/2024	N/A	DMAC DiaMedica Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A
3/8/2024	12/31/2023	BPTH Bio-Path	-$5.40	-$5.40	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPTH Bio-Path	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
INNT Innovate Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
VTL Vital Therapies	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPTH Bio-Path	N/A	1.60	1.60
DMAC DiaMedica Therapeutics	N/A	19.27	19.27
INNT Innovate Biopharmaceuticals	N/A	0.35	0.35
VTL Vital Therapies	N/A	6.97	6.97

Ownership

Institutional Ownership

Company	Institutional Ownership
BPTH Bio-Path	5.74%
DMAC DiaMedica Therapeutics	10.12%
INNT Innovate Biopharmaceuticals	5.88%
VTL Vital Therapies	15.52%

Insider Ownership

Company	Insider Ownership
BPTH Bio-Path	3.05%
DMAC DiaMedica Therapeutics	7.20%
INNT Innovate Biopharmaceuticals	7.90%
VTL Vital Therapies	33.90%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BPTH Bio-Path	10	680,000	658,000	Optionable
DMAC DiaMedica Therapeutics	18	37.96 million	35.23 million	Optionable
INNT Innovate Biopharmaceuticals	8	41.33 million	N/A	Not Optionable
VTL Vital Therapies	10	42.37 million	N/A	Not Optionable

VTL, BPTH, DMAC, and INNT Headlines

Source	Headline
	Don’t Forget About Vital Signs in Psychiatry Visits psychologytoday.com - March 12 at 6:46 PM
	What is therapeutic recreation? Champaign counselors train to include it in their sessions yahoo.com - March 8 at 1:39 AM
	Teen Therapy and Psychiatry Online: Hit or Miss? medpagetoday.com - March 3 at 2:54 PM
	Vital Ltd VTL morningstar.com - March 2 at 9:53 AM
	The Benefits of Teen Outpatient Programs for Behavioral Health msn.com - March 2 at 12:29 AM
	Vital Ltd. wsj.com - March 1 at 7:29 PM
	‘Vital’ new treatment center for high-risk kids seeks $8 million in funding from Oregon lawmakers news.yahoo.com - February 29 at 7:34 PM
	North Carolina tells nature-based therapy program to stop admissions during probe of boy’s death msn.com - February 13 at 8:59 PM
	Is IV therapy safe? What to know about the growing industry and its expansion in Houston houstonchronicle.com - January 28 at 4:15 AM
	Executive Summary: New York State Fiscal Year 2024-2025 Budget jdsupra.com - January 26 at 5:57 PM
	5 for Good: Therapeutic riding program helps build strength, social skills msn.com - December 7 at 9:21 PM
	Why High-Quality Raw Materials Are Vital \| Producing Therapeutic Cardiomyocytes from iPSC Stem Cells fiercebiotech.com - November 30 at 12:51 PM
	Is Online Therapy Effective? laweekly.com - November 28 at 7:00 PM
	Understanding T lymphocytes inner workings to harness therapeutic potential openaccessgovernment.org - November 13 at 8:09 AM
	Baxter’s Proposed Kidney Spinoff Business Gets a Name mddionline.com - November 2 at 12:05 AM
	LYT-100 well tolerated in healthy adults at higher doses than Esbriet pulmonaryfibrosisnews.com - October 13 at 5:50 PM
	Streamlining Mental Health Services: A Look Into Online Therapy Platforms techbullion.com - October 9 at 10:38 AM
	Local Latina working to provide mental health services to all ktnv.com - October 2 at 7:25 PM
	Vital Signs \| The latest on leukemia and lymphoma treatment options dailyprogress.com - September 12 at 4:08 PM
	World Physical Therapy Day 2023: Date, history, theme, significance and all you need to know msn.com - September 7 at 10:49 AM
	Executive Speaker Series uwyo.edu - August 11 at 1:42 AM
	Best Online Therapy For Anxiety Of 2023 forbes.com - August 8 at 1:39 PM
	Medical Family Therapy Program slu.edu - July 29 at 7:29 PM
	Vital Proteins Collagen Peptides Review 2023 forbes.com - July 21 at 1:23 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bio-Path

NASDAQ:BPTH

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

DiaMedica Therapeutics

NASDAQ:DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Innovate Biopharmaceuticals

NASDAQ:INNT

Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.

Vital Therapies

NASDAQ:VTL

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial